OBJECTIVES: To assess public preferences for the predictive genetic test for Alzheimer’s disease in the United States METHODS: A rating conjoint analysis was conducted using an anonymous online survey distributed by Qualtrics® to a general population panel in April 2011 in the United States. The study design included three attributes: Accuracy, Treatment Availability, and Anonymity. A total of 12 scenarios were used to elicit people’s preference by adopting an 11-point scale. The respondents also stated their highest willingness-to-pay (WTP) for each scenario by answering the open-ended questions. RESULTS: A total of 295 responses were collected over four days. The results showed the most important attribute for the aggregate model was Accuracy, contributing 64.73% to the preference rating. Treatment Availability and Anonymity contributed 20.72% and 14.59% to the preference rating, respectively. The most preferred scenario was the test with a 100% chance of being correct, a cure for AD is available and the test result is anonymous. The median WTP for the highest-rating scenario (Accuracy 100%, a cure is available, test result is anonymous) was $100 (mean WTP was $276). The median WTP for the lowest-rating scenario (Accuracy 40%, no cure but drugs for symptom relief, not anonymous) was zero (mean WTP was $36). Four groups were identified using cluster analysis revealing different patterns of importance among the three attributes. CONCLUSIONS: The results of this study highlight the attributes consumer find important when making the decision to obtain an AD genetic test. These results should be of interests to policy makers, genetic test developers and health care providers.